Evidence map›Paper›PMID 25575639›Full record

ArticleMolecular neurodegeneration2015

Ubiquitin-specific protease 14 regulates c-Jun N-terminal kinase signaling at the neuromuscular junction.

Jada H Vaden, Bula J Bhattacharyya, Ping-Chung Chen, Jennifer A Watson, Andrea G Marshall, Scott E Phillips, Julie A Wilson, Gwendalyn D King, Richard J Miller, Scott M Wilson

Open access · goldAbstract read
In one paragraph

Article in Molecular neurodegeneration, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 51 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. NMJ-related diseases beyond the congenital myasthenic syndromes.Frontiers in cell and developmental biology · 2023
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Deubiquitination Reactions on the Proteasome for Proteasome Versatility.International journal of molecular sciences · 2020
    Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Jada H VadenDepartment of Neurobiology, University of Alabama at Birmingham, Civitan International Research Center, Evelyn F. McKnight Brain Institute, 1825 University Blvd, Birmingham, AL, 35294, USA. jjh85@uab.edu.
Bula J BhattacharyyaDepartment of Molecular Pharmacology and Biological Chemistry, Northwestern University, 303 East Chicago Ave, Chicago, IL, 60611, USA. bula@northwestern.edu.
Ping-Chung ChenDepartment of Structural Biology, St. Jude Children's Research Hospital, Danny Thomas Place, Memphis, TN, 38105-3678, USA. Ping-Chung.Chen@stjude.org.
Jennifer A WatsonDepartment of Neurobiology, University of Alabama at Birmingham, Civitan International Research Center, Evelyn F. McKnight Brain Institute, 1825 University Blvd, Birmingham, AL, 35294, USA. jawatson@uab.edu.
Andrea G MarshallDepartment of Physiology, Neurobiology and Behavior, University of California, Davis, California, CA, USA. agail22@uab.edu.
Scott E PhillipsDepartment of Neurobiology, University of Alabama at Birmingham, Civitan International Research Center, Evelyn F. McKnight Brain Institute, 1825 University Blvd, Birmingham, AL, 35294, USA. scottep@uab.edu.
Julie A WilsonDepartment of Neurobiology, University of Alabama at Birmingham, Civitan International Research Center, Evelyn F. McKnight Brain Institute, 1825 University Blvd, Birmingham, AL, 35294, USA. wilsonja@uab.edu.
Gwendalyn D KingDepartment of Neurobiology, University of Alabama at Birmingham, Civitan International Research Center, Evelyn F. McKnight Brain Institute, 1825 University Blvd, Birmingham, AL, 35294, USA. gdking@uab.edu.
Richard J MillerDepartment of Molecular Pharmacology and Biological Chemistry, Northwestern University, 303 East Chicago Ave, Chicago, IL, 60611, USA. r-miller10@northwestern.edu.
Scott M WilsonDepartment of Neurobiology, University of Alabama at Birmingham, Civitan International Research Center, Evelyn F. McKnight Brain Institute, 1825 University Blvd, Birmingham, AL, 35294, USA. wilson@nrc.uab.edu.
University of Alabama at Birmingham · USNorthwestern University · USSt. Jude Children's Research Hospital · USUniversity of California, Davis · US

Funding

The role of Usp14 in regulating neuronal functionR01NS047533 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WILSON, SCOTT MICHAEL · 2004 to 2014
$3.1M
Enhancement of Proteasome Activity for the Treatment of Neurological DisordersR21NS074456 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WILSON, SCOTT MICHAEL · 2011 to 2012
$403k
Howard Hughes Medical InstituteNINDS NIH HHS R01 NS047533NINDS NIH HHS R21 NS074456
6 · The paper itself

Abstract

backgroundUbiquitin-specific protease 14 (USP14) is one of three proteasome-associated deubiquitinating enzymes that remove ubiquitin from proteasomal substrates prior to their degradation. In vitro evidence suggests that inhibiting USP14's catalytic activity alters the turnover of ubiquitinated proteins by the proteasome, although whether protein degradation is accelerated or delayed seems to be cell-type and substrate specific. For example, combined inhibition of USP14 and the proteasomal deubiquitinating enzyme UCH37 halts protein degradation and promotes apoptosis in multiple myeloma cells, whereas USP14 inhibition alone accelerates the degradation of aggregate-prone proteins in immortalized cell lines. These findings have prompted interest in USP14 as a therapeutic target both inside and outside of the nervous system. However, loss of USP14 in the spontaneously occurring ataxia mouse mutant leads to a dramatic neuromuscular phenotype and early perinatal lethality, suggesting that USP14 inhibition may have adverse consequences in the nervous system. We therefore expressed a catalytically inactive USP14 mutant in the mouse nervous system to determine whether USP14's catalytic activity is required for neuromuscular junction (NMJ) structure and function.

resultsMice expressing catalytically inactive USP14 in the nervous system exhibited motor deficits, altered NMJ structure, and synaptic transmission deficits that were similar to what is observed in the USP14-deficient ataxia mice. Acute pharmacological inhibition of USP14 in wild type mice also reduced NMJ synaptic transmission. However, there was no evidence of altered proteasome activity when USP14 was inhibited either genetically or pharmacologically. Instead, these manipulations increased the levels of non-proteasome targeting ubiquitin conjugates. Specifically, we observed enhanced proteasome-independent ubiquitination of mixed lineage kinase 3 (MLK3). Consistent with the direct activation of MLK3 by ubiquitination, we also observed increased activation of its downstrea targets MAP kinase kinase 4 (MKK4) and c-Jun N-terminal kinase (JNK). In vivo inhibition of JNK improved motor function and synapse structure in the USP14 catalytic mutant mice.

conclusionsUSP14's catalytic activity is required for nervous system structure and function and has an ongoing role in NMJ synaptic transmission. By regulating the ubiquitination status of protein kinases, USP14 can coordinate the activity of intracellular signaling pathways that control the development and activity of the NMJ.

Indexed as

AnimalsAnthracenesAtaxiaCatalysisCells, CulturedCerebral CortexExploratory BehaviorFemaleHand StrengthJNK Mitogen-Activated Protein KinasesMaleMiceMice, Inbred C57BLMice, Neurologic MutantsMice, TransgenicMutagenesis, Site-Directed1-(1-(4-fluorophenyl)-2,5-dimethylpyrrol-3-yl)-2-pyrrolidin-1-ylethanoneAnthracenesJNK Mitogen-Activated Protein KinasesNerve Tissue ProteinsProteasome Endopeptidase ComplexpyrazolanthronePyrrolesPyrrolidinesUbiquitin ThiolesteraseUsp14 protein, mouse

Identifiers

PMID25575639
PMCPMC4417291
OpenAlexW2107475738

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.